Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials

Blood

Volumn 105, Issue 5, 2005, Pages 1891-1897

  Spina, Michele ^b   Jaeger, Ulrich ^b   Sparano, Joseph A ^b   Talamini, Renato ^b   Simonelli, Cecilia ^b   Michieli, Mariagrazia ^b   Rossi, Giuseppe ^b   Nigra, Ezio ^b   Berretta, Massimiliano ^b   Cattaneo, Chiara ^b   Rieger, Armin C ^b   Vaccher, Emanuela ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BACTERIAL PNEUMONIA; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CRYPTOSPORIDIOSIS; FEBRILE NEUTROPENIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETINITIS; SALMONELLOSIS; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; VIRUS LOAD; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFECTION; INFUSIONS, INTRAVENOUS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 20144367599     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3300     Document Type: Article

References (36)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
3. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992;80:8-20.
4. Kaplan LD, Strauss DJ. Testa MA, et al. Lowdose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641-1648.
5. Gisselbrecht C, Oksenhendler E, Tirelli U, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy: French-Italian Cooperative Group. Am J Med. 1993;95:188-196.
6. Gisselbrecht C, Spina M, Gabarre J, et al. Therapy of HIV-related non-Hodgkin's lymphoma: a European multicentric randomized study in patients stratified according to their prognostic factors: preliminary results [abstract]. J Acquir Immune Defic Syndr. 1997;14:A53, Abstract 149.
7. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 2001;98:2339-2344.
8. Gérard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Synd Hum Retrovirol. 2002;30:478-484.
9. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin's lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1556-1564.
10. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142 - Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor: National Institute of Allergy and Infectious Diseases. J Clin Oncol. 1998;16:3601-3606.
11. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol. 2004;22:1491-1500.
12. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule dependent effect favoring infusional administration of chemotherapy. J Clin Oncol. 1993;11:1071-1079.
13. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-l-related non-Hodgkin's lymphoma: a highly active regimen. Blood. 1993;81:2810-2815.
14. Coiffer B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
15. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
16. Demiden A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
17. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
18. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.
19. Spina M, Sparano JA, Jaegaer U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS. 2003;17:137-138.
20. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on non-Hodgkin's Disease Classification. Cancer Res. 1971;31:1860-1861.
21. Miller AB, Hoogstragen B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
24. Cox DR. Regression models and life tables. J R Stat Soc Br. 1972;34:187-202.
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive lymphoma. N Engl J Med. 1993;329:987-994.
26. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171-2178.
27. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
28. Pfreundschuh MG. Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients < 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc Am Soc Clin Oncol. 2004;23:556. Abstract 6500.
29. Kaplan LD, Scadden DT. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS Malignancies Consortium Study 010. Proc Am Soc Clin Oncol. 2003;22:564. Abstract 2268.
30. Bower M, McCall-Peat N, Ryan N, et al. Protease Inhibitors potentiate chemotherapy induced neutropenia. Blood. 2004;104:2943-2946.
31. Boue F, Gabarre J, Gisselbrecht C, et al. CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma: results of an ANRS trial. Proc Am Soc Hematol. 2002;470. Abstract 1824.
32. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EP-OCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653-4659.
33. Wilson WH, Grossbard ML, Pitaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685-2693.
34. Sparano JA, Weller E, Nazeer T, Habermann TM, Traynor, A, Cassileth P. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor prognosis intermediate- or high-grade non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002;100:1634-1640.
35. Sparano JA, Wiernik PH, Hu X, et al. A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:3026-3035.
36. AIDS-Associated Malignancies Clinical Trials Consortium. A randomized phase II trial of epoch given either concurrently or sequentially with rituximab in patients with intermediate- or high-grade HIV-associated B-cell Non-Hodgkin's lymphoma. Available at: http://www.amc.uab.edu/034des.htm. Accessed December 4, 2004.